IP Library Patent Application 16495974
Patent Application
App. No. 16/495,974

METHODS FOR ENHANCING YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/495,974
Abstract

The invention provides methods for the production of recombinant adeno-associated virus vectors (rAAV), e.g., comprising the addition of a surfactant, e.g., Triton X-100, to a producer cell culture medium.

Claims (53)

1 . A method of producing a clarified recombinant adeno-associated virus vector (rAAV) product comprising the steps of:

(a) incubating a plurality of producer cells in a cell culture medium under conditions that promote release of rAAV particles, whereby rAAV particles are released from the producer cells into the culture medium, and the producer cells are not substantially lysed;

(b) recovering the cell culture medium from the producer cells, so that the recovered cell culture medium is substantially free of intact producer cells and contains rAAV particles;

(c) adding a surfactant to the recovered cell culture medium, wherein the surfactant is a non-ionic surfactant with a hydrophilic-lipophilic balance (HLB) between 12 and 15; and

(d) passing the recovered cell culture medium containing the surfactant through a first filter;

wherein the method does not comprise a step of lysing the producer cells.

2 . The method of claim 1 , wherein the step of recovering the cell culture medium from the producer cells, so that the recovered cell culture medium is substantially free of intact producer cells and contains rAAV particles, comprises the sub-steps of:

(i.) centrifuging the producer cells in the cell culture medium to create a cell pellet; and

(ii.) separating the cell culture medium from the cell pellet, and retaining the cell culture medium.

3 . The method of claim 2 , wherein the producer cells in the cell culture medium are centrifuged at a speed of greater than 150×g or 300×g.

4 . The method of claim 2 or 3 , wherein the producer cells in the cell culture medium are centrifuged at a speed of less than 500×g or 13,000×g.

5 . The method of any preceding claim, wherein the step of recovering the cell culture medium from the producer cells, so that the recovered cell culture medium is substantially free of intact producer cells and contains rAAV particles, comprises the sub-step of aspirating the cell culture medium into a vessel.

6 . The method of any preceding claim, wherein the step of recovering the cell culture medium from the producer cells, so that the recovered cell culture medium is substantially free of intact producer cells and contains rAAV particles, comprises the sub-step of changing the pH of the cell culture medium.

7 . A method of producing a clarified recombinant adeno-associated virus vector (rAAV) product comprising the steps of:

(a) incubating a plurality of producer cells in a cell culture medium under conditions that promote release of rAAV particles, whereby rAAV particles are released from the producer cells into the culture medium, and the producer cells are not substantially lysed;

(b) adding a surfactant to the cell culture medium, wherein the surfactant is a non-ionic surfactant with a hydrophilic-lipophilic balance (HLB) between 12 and 15;

(c) incubating the producer cells in the surfactant-containing cell culture medium for a time, the time being insufficient to cause the lysis of 50% of the producer cells; and

(d) passing the cell culture medium containing the surfactant through a first filter.

8 . The method of claim 7 , wherein incubation in the surfactant-containing cell culture medium results in lysis of fewer than 40% of the producer cells.

9 . The method of claim 8 , wherein incubation in the surfactant-containing cell culture medium results in lysis of fewer than 30% of the producer cells.

10 . The method of claim 9 , wherein incubation in the surfactant-containing cell culture medium results in lysis of fewer than 10% of the producer cells.

11 . The method of claim 10 , wherein incubation in the surfactant-containing cell culture medium results in lysis of fewer than 1% of the producer cells.

12 . The method of any preceding claim, wherein release of the rAAV particles from the producer cells into the culture medium results in lysis of fewer than 50% of the producer cells.

13 . The method of any preceding claim, wherein release of the rAAV particles from the producer cells into the culture medium results in lysis of fewer than 30% of the producer cells.

14 . The method of any preceding claim, wherein release of the rAAV particles from the producer cells into the culture medium results in lysis of fewer than 10% of the producer cells.

15 . The method of any preceding claim, wherein release of the rAAV particles from the producer cells into the culture medium results in lysis of fewer than 1% of the producer cells.

16 . The method of any preceding claim, wherein the surfactant is added to the cell culture medium at a final concentration of about 1% to about 0.01%.

17 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 0.1% to about 0.5%.

18 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 0.1% to about 0.3%.

19 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 0.5% to about 1%.

20 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 0.7% to about 1%.

21 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 1%.

22 . The method of claim 16 , wherein the surfactant is added to the cell culture medium at a final concentration of about 0.1%.

23 . The method of any preceding claim, further comprising step (e), passing the cell culture medium containing the surfactant through a second filter.

24 . The method of any preceding claim, wherein one or more of the filters are selected from the group consisting of a PES membrane filter, a PVDF membrane filter, a nylon membrane filter, and a MCE membrane filter.

25 . The method of claim 24 , wherein one or more of the filters is a PES membrane filter.

26 . The method of any preceding claim, wherein the filter has a pore size of less than 1 μm.

27 . The method of claim 26 , wherein the filter has a pore size of less than 0.5 μm.

28 . The method of claim 27 , wherein the filter has a pore size of 0.22 μm.

29 . The method of any preceding claim, wherein the concentration of rAAV particles in the rAAV-containing cell culture medium after the first filtration step is greater than 80% of the concentration of rAAV particles in the rAAV-containing cell culture medium immediately prior to the first filtration step.

30 . The method of claim 29 , wherein the concentration of rAAV particles in the rAAV-containing cell culture medium after the first filtration step is greater than 90% of the concentration of rAAV particles in the rAAV-containing cell culture medium immediately prior to the first filtration step.

31 . The method of claim 30 , wherein the concentration of rAAV particles in the rAAV-containing cell culture medium after the first filtration step is greater than 95% of the concentration of rAAV particles in the rAAV-containing cell culture medium immediately prior to the first filtration step.

32 . The method of claim 31 , wherein the concentration of rAAV particles in the rAAV-containing cell culture medium after the first filtration step is greater than 99% of the concentration of rAAV particles in the rAAV-containing cell culture medium immediately prior to the first filtration step.

33 . The method of any preceding claim, wherein the surfactant is an octylphenol ethoxylate.

34 . The method of claim 33 , wherein the surfactant is an octylphenol ethoxylate with an HLB between 13 and 14.

35 . The method of claim 33 , wherein the surfactant is an octylphenol ethoxylate with an average polyethylene oxide chain length between 8 and 12.

36 . The method of claim 33 , wherein the surfactant is an octylphenol ethoxylate with an average polyethylene oxide chain length between 9 and 10.

37 . The method of any preceding claim, wherein the producer cells are mammalian cells.

38 . The method of claim 37 , wherein the producer cells are selected from the group consisting of HeLa, HEK293, COS, A549, and Vero cells.

39 . The method of claim 38 , wherein the producer cells are HeLa cells.

40 . The method of any one of claims 1 - 36 , wherein the producer cells are insect cells.

41 . The method of claim 40 , wherein the insect cells are selected from the group consisting of Sf9, Sf-21, Tn-368, and BTI-Tn-5B1-4 (High-Five) cells.

42 . A rAAV produced by the method of any preceding claim.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2022
From: JING, YING; PANTELI, JAN; CLARK, KELLY R.
To: DIMENSION THERAPEUTICS, INC.
Reel/Frame 059046/0615 →
MERGER AND CHANGE OF NAME Recorded Feb 18, 2022
From: DIMENSION THERAPEUTICS, INC.; ULTRAGENYX PHARMACEUTICAL INC.
To: ULTRAGENYX PHARMACEUTICAL INC.
Reel/Frame 059046/0858 →